The chronic kidney disease (CKD) anemia market across the seven major markets (7MM*) is forecast to grow at a compound annual growth rate (CAGR) of 1.7% from $4.4 billion in 2024 to $5.3 billion in 2034, according to GlobalData, a leading data and analytics company.

GlobalData’s latest report “Chronic Kidney Disease Anemia: Opportunity Assessment and Forecast,” reveals that the US dominated the CKD market in 2024, representing 48.8% of sales in the 7MM. The US is expected to remain as the leading market throughout the forecast period, generating sales of $2.7 billion in 2034, representing 52.7% of the overall market across the 7MM. This dominating position within the 7MM is a result of the significantly higher costs of marketed products in the US and a high diagnosed prevalence.

Kajal Jaddoo, Senior Pharma Analyst at GlobalData, comments: “The CKD anemia market is relatively well established. However, despite several treatment options, there is still room for improvement and innovation in the CKD anemia treatment space.”

Key opinion leaders (KOLs) interviewed by GlobalData noted that a key unmet need within the CKD anemia space is for therapies that are efficacious without the side effects associated with the long-term use of iron therapies. Besides the hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) class of drugs and efesa (efepoetin alfa), the pipeline of novel CKD anemia treatments across the 7MM is considered to be sparse.

According to GlobalData forecasts, the overall diagnosed prevalence of CKD anemia cases is expected to increase at an annual growth rate (AGR) of 0.87% in the 7MM.

Jaddoo concludes: “Potential barriers to growth of the global CKD anemia market include the loss of exclusivity of several key branded products that are expected to face patent and data exclusivity expiration, leading to brand erosion due to the emergence of biosimilars and generics.”

*7MM – The US, France, Germany, Italy, Spain, the UK, and Japan